comparemela.com

Latest Breaking News On - ஸ்டிபேல் நிக்கோலஸ் யூரோப் வரையறுக்கப்பட்டவை கூட்டு தரகர் - Page 10 : comparemela.com

Investegate |Avacta Group PLC Announcements | Avacta Group PLC: Results of Initial Evaluation of SARS-CoV-2 LFT

Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer ® biologics and pre|CISION™ tumour targeted chemotherapies.   The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal s immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture.   Avacta s pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these powerful an

PetroTal advises of Gran Tierra ownership reduction

PetroTal advises of Gran Tierra ownership reduction PetroTal” or the “ Company“) advises that, as announced by Gran Tierra Energy Inc. (“GTEI”) on January 20, 2021, Gran Tierra Resources Limited (“GTRL”) has sold an aggregate of 109,006,250 common shares in the Company (“Common Shares”). The Company understands that multiple entities purchased the shares sold by GTRL and that, following the sale, GTRL continues to hold 137,093,750 Common Shares, representing 16.8% of PetroTal’s issued and outstanding Common Shares. PetroTal was not a party to the agreements and did not receive any proceeds from the sale transactions. Source: PR Newswire The Company has 816,167,379 Common Shares in issue and there are no shares held in treasury. For purposes of the Disclosure Guidance and Transparency Rules, the total number of voting rights (TVR) in the Company is 816,167,379. This figure may be used by shareholders as the denominator for the calculations by which they determi

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.